Anti-DLL3 [HP-92]

Description:

Recombinant monoclonal antibody to DLL3. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the alpaca peripheral lymphocytes HP-92.

Clone Name:

HP-92

Published Application(s):

ELISA, FC

Published Species Reactivity:

Human

Products based on this clone:

{{heading}}

Please Select

Ab03572-1.159 Anti-DLL3 [HP-92]
Human
Mouse IgG1-Fc fusion
Purified
Ships in 5-6 weeks

Ab03572-10.159 Anti-DLL3 [HP-92]
Human
Human IgG1-Fc fusion
Purified
Ships in 5-6 weeks

Ab03572-23.159 Anti-DLL3 [HP-92]
Human
Rabbit IgG-Fc fusion
Purified
Ships in 5-6 weeks

UniProt Accession Number of Target Protein: Q9NYJ7

Alternative Name(s) of Target: Delta-like protein 3; Drosophila Delta homolog 3 (Delta3)
Immunogen: The original antibody was generated by immunizing two alpacas with human DLL3.

Specificity: This antibody binds human Delta-like protein 3 (DLL3), which is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Mature human DLL3 consists of a 466 amino acid (aa) extracellular domain (ECD) with one DSL domain and six EGF-like repeats, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain. It is an inhibitory Notch ligand that is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC.

Application Notes: The binding affinity to human DLL3 that is comparable with Rovalpituzumab. The binding characterization of this antibody for human DLL3 was done using ELISA. This antibody was capable of binding DLL3 expressed on the surface of H446 and H524 small cell lung cancer cell lines using flow cytometry (CN114057880).

Antibody first published in: PMID: